Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Non-Current Assets (2016 - 2025)

Cardiff Oncology's Non-Current Assets history spans 15 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 17.79% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $7.9 million, down 41.9%, while the annual FY2025 figure was $1.8 million, 17.79% down from the prior year.
  • Non-Current Assets for Q4 2025 was $1.8 million at Cardiff Oncology, down from $2.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.9 million in Q4 2022 and bottomed at $863000.0 in Q2 2021.
  • The 5-year median for Non-Current Assets is $3.6 million (2021), against an average of $3.2 million.
  • The largest annual shift saw Non-Current Assets soared 345.77% in 2022 before it crashed 49.44% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $3.4 million in 2021, then soared by 43.61% to $4.9 million in 2022, then fell by 13.9% to $4.2 million in 2023, then plummeted by 49.44% to $2.1 million in 2024, then dropped by 17.79% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Non-Current Assets are $1.8 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025).